Centro Regional Integrado de Oncologia

Fortaleza, Ceará 60336-045

1 studies enrolling now · 5 studies all time

What they study most

Adjuvant, Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, Breast Cancer, EGFR, Early Stage Lung Cancer, Exon 20, HER2+ Metastatic Breast Cancer (MBC), Lung Cancer, NSCLC, Stage IB-IIIA, Post-surgical, Uncommon EGFR Mutations

Studies at this site

• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer — Running, not enrolling
• Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study — Enrolling by invitation
• A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting — Completed